Citations

Mayo Clinic

Clear

1430 citation(s) found for "Qi, Nathan".

Detection and Quantification of Hepatitis C Virus (HCV) by MultiCode-RTx Real-Time PCR Targeting the HCV 3′ Untranslated Region
Mulligan, Elizabeth K., Germer, Jeffery J., Arens, Max Q., D'Amore, Krista L., Bisceglie, Adrian M. Di , Ledeboer, Nathan A., Moser, Michael J., Newman, Andrew, O'Guin, Andy K., Olivo, Paul D. , Podzorski, Diane, Vaughan, Kimberly A., Yao, Joseph D. , Elagin, Slava, Johnson, Scott C.

Journal of Clinical Microbiology | June 18, 2009 | Volume: 47 | Issue: 8 | Pages: 2635-2638

10.1128/jcm.02170-08 | PMID 19535519 Get It

ABSTRACT A prototype, real-time reverse-transcription PCR assay, based on MultiCode-RTx technology, quantifying hepatitis C virus (HCV) RNA by targeting the HCV 3′ untranslated region demonstrated linearity over 7 logs, with a good correlation between the quantitative results of this assay and the results of two commercially available comparator assays for 466 clinical specimens comprising all six HCV genotypes.
Clinical and electrodiagnostic correlates of peroneal intraneural ganglia
Sorenson, Eric J. , Spinner, Robert J. , Daube, Jasper R., Young, Nathan P.

Neurology | February 2, 2009 | Volume: 72 | Issue: 5 | Pages: 447-452

10.1212/01.wnl.0000341787.70467.99 | PMID 19188576 Get It

Editorial Comment
Hoffman, Nathan, Reinberg, Yuri

Journal of Urology | December 17, 2008 | Volume: 180 | Issue: 5 | Pages: 2158-2158

10.1016/j.juro.2008.07.134 Get It

Effect of Antibiotic Pretreatment on Cerebrospinal Fluid Profiles of Children With Bacterial Meningitis
Nigrovic, Lise E. , Malley, Richard , Macias, Charles G. , Kanegaye, John T. , Moro‐Sutherland, Donna, Schremmer, Robert D., Schwab, Sandra H., Agrawal, Dewesh , Mansour, Karim, Bennett, Jonathan E. , Katsogridakis, Yiannis , Mohseni, Michael , Bulloch, Blake, Steele, Dale W. , Kaplan, Ron L. , Herman, Martin I., Bandyopadhyay, Subhankar, Truong, Uyen , Wang, Vince J., Bonsu, Bema K., Chapman, Jennifer, Kuppermann, Nathan , Dayan, Peter , Wang, Vincent J. , Mohseni, Michael M

Pediatrics | October 1, 2008 | Volume: 122 | Issue: 4 | Pages: 726-730

10.1542/peds.2007-3275 | PMID 18829794 Get It

OBJECTIVE. The goal of this study was to evaluate the effect of antibiotic administration before lumbar puncture on cerebrospinal fluid profiles in children with bacterial meningitis. METHODS. We reviewed the medical records of all children (1 month to 18 years of age) with bacterial meningitis who presented to 20 pediatric emergency departments between 2001 and 2004. Bacterial meningitis was defined by positive cerebrospinal fluid culture results for a bacterial pathogen or cerebrospinal fluid pleocytosis with positive blood culture and/or cerebrospinal fluid latex agglutination results. Probable bacterial meningitis was defined as positive cerebrospinal fluid Gram stain results with negative results of bacterial cultures of blood and cerebrospinal fluid. Antibiotic pretreatment was defined as any antibiotic administered within 72 hours before the lumbar puncture. RESULTS. We identified 231 patients with bacterial meningitis and another 14 with probable bacterial meningitis. Of those 245 patients, 85 (35%) had received antibiotic pretreatment. After adjustment for patient age, duration and severity of illness at presentation, and bacterial pathogen, longer duration of antibiotic pretreatment was not significantly associated with cerebrospinal fluid white blood cell count, cerebrospinal fluid absolute neutrophil count. However, antibiotic pretreatment was significantly associated with higher cerebrospinal fluid glucose and lower cerebrospinal fluid protein levels. Although these effects became apparent earlier, patients with ≥12 hours of pretreatment, compared with patients who either were not pretreated or were pretreated for <12 hours, had significantly higher median cerebrospinal fluid glucose levels (48 mg/dL vs 29 mg/dL) and lower median cerebrospinal fluid protein levels (121 vs 178 mg/dL). CONCLUSIONS. In patients with bacterial meningitis, antibiotic pretreatment is associated with higher cerebrospinal fluid glucose levels and lower cerebrospinal fluid protein levels, although pretreatment does not modify cerebrospinal fluid white blood cell count or absolute neutrophil count results.
Prognostic Impact of Bim, Puma, and Noxa Expression in Human Colon Carcinomas
Rego, Rafaela L. , Foster, Nathan R. , Sargent, Daniel J. , Windschitl, Harold E., Sinicrope, Frank A. , Okumura, Kenji , O’Connell, Michael J. , Sargent, Daniel J

Clinical Cancer Research | September 15, 2008 | Volume: 14 | Issue: 18 | Pages: 5810-5818

10.1158/1078-0432.ccr-07-5202 | PMID 18794091 Get It

Abstract Purpose: Proapoptotic BH3-only proteins (Bim, Bad, Bid, Puma, and Noxa) initiate apoptosis by binding to regulatory sites on antiapoptotic Bcl-2 proteins, directly neutralizing their cytoprotective function. Expression of these proteins in colon cancer patients may account for differences in recurrence and survival rates. Experimental Design: Archival tumor-node-metastasis stage II and III primary colon carcinomas from patients treated in 5-fluorouracil–based adjuvant therapy trials were studied. Immunohistochemical analysis of Bim, Puma, and Noxa proteins was done using tissue microarrays (n = 431). Immunoscores were determined and correlated with clinicopathologic variables and disease-free survival (DFS) and overall survival (OS) rates. Results: Elevated expression of proapoptotic Bim (hazard ratio, 0.65; 95% confidence interval, 0.44-0.97; P = 0.033) and Puma (hazard ratio, 0.59; 95% confidence interval, 0.37-0.93; P = 0.022), but not Noxa, proteins in the tumor cytoplasm was significantly associated with more favorable OS in a univariate analysis, and elevated Bim expression was also associated with better DFS (P = 0.023). Patient age, tumor stage, and histologic grade were also prognostic. Multivariate Cox analysis showed that Bim (DFS, P = 0.030; OS, P = 0.045) and Puma (OS, P = 0.037) expression were independent predictors of OS after adjustment for histologic grade, tumor stage, age, and treatment. Furthermore, the combined variable of Bim and Puma was highly discriminant for both DFS (P = 0.0034) and OS (P = 0.0011). Conclusions: The proapoptotic BH3-only proteins Bim and Puma can provide prognostic information for stage II and III colon cancer patients receiving 5-fluorouracil–based adjuvant chemotherapy. Furthermore, our results support BH3-only proteins as molecular targets of novel anticancer drugs.
O1‐03–03: Reduced β‐amyloid deposition in amyloid precursor protein transgenic mice lacking the insulin‐degrading enzyme
Guénette, Suzanne Y., Wang, Lirong , Robak, Angela, Eckman, Christopher B., Tanzi, Rudolph E. , Eckman, Elizabeth A. , Mathews, Paul M.

Alzheimer's & Dementia | July 24, 2008 | Volume: 4 | Issue: 4S_Part_3 | Pages: No page available

10.1016/j.jalz.2008.05.231 Get It

18 F-FDG PET in the Management of Patients with Anaplastic Thyroid Carcinoma
Bogsrud, Trond Velde , Karantanis, Dimitrios, Nathan, Mark A., Mullan, Brian P., Wiseman, Gregory A., Kasperbauer, Jan L. , Reading, Carl C., Lowe, Val J. , Hay, Ian

Thyroid® | July 17, 2008 | Volume: 18 | Issue: 7 | Pages: 713-719

10.1089/thy.2007.0350 | PMID 18630999 Get It

Background: Anaplastic thyroid carcinoma (ATC) is one of the most aggressive solid tumors in humans. The use of positron emission tomography (PET) with 18 F-fluorodeoxyglucose ( 18 F-FDG) in ATC has not been studied, and only a few case reports have been published. The objective of this study was to investigate the potential contribution of 18 F-FDG PET to the clinical management of patients with ATC. Methods: All patients with ATC studied with 18 F-FDG PET from August 2001 through March 2007 were included. The PET results were correlated with computed tomography, ultrasound, magnetic resonance imaging, bone scan, histology, and clinical follow-up. The FDG uptake was semiquantified as maximum standard uptake value. Any change in the treatment plan as a direct result of the PET findings as documented in the clinical notes was recorded. Results: Sixteen patients were included. True-positive PET findings were seen for all primary tumors, in all nine patients with lymph node metastases, in five out of eight patients with lung metastases, and in two patients with distant metastases other than lung metastases. In 8 of the 16 patients, the medical records reported a direct impact of the PET findings on the clinical management. Conclusions: ATC demonstrates intense uptake on 18 F-FDG PET images. In 8 of the 16 patients (50%), the medical records reported a direct impact of the PET findings on the management of the patient. PET may improve disease detection and have an impact on the management of patients with ATC relative to other imaging modalities.
Integrating Physicians, Researchers and Engineers—60Years of Medical Device Innovation at Mayo Clinic
Horne, April E., Bennet, Kevin A., Buntrock, Nathan C., Halovsen, Thomas G., Wehde, Mark

Journal of Medical Devices | July 10, 2008 | Volume: 2 | Issue: 2 | Pages: No page available

10.1115/1.2924269 Get It

Medical innovation is often delayed by the difficulty in developing cooperation among practicing physicians, academics and medical device developers. In Rochester, Minnesota, the Mayo Clinic Division of Engineering has excelled at integrating these specialties, facilitating medical device innovation for the past 60years. In 1948, Mayo Clinic combined an instrument shop with an engineering design services team and created the Division of Engineering. This enabled a unique partnership between physicians, researchers, and product developers. Early innovations from this team include the Mayo heart-lung machine, cardiac monitoring, advances in aero-medicine, surgical stereotaxy, and early transfusion equipment. Today, the Mayo Division of Engineering consists of mechanical, chemical, electrical, biomedical, and software engineers, machinists, and a scientific glass-blower. The division works in close collaboration with project proponents (primarily physicians) within the clinical environment to analyze problems, propose designs, and deliver a clinical solution. From custom 3-D models for support pre-surgical planning to endoscopic heart valve repair devices, the team identifies opportunities and delivers systems that can be quickly translated into medical practice.
Proapoptotic Bad and Bid Protein Expression Predict Survival in Stages II and III Colon Cancers
Rego, Rafaela L. , Foster, Nathan R. , Thibodeau, Stephen N. , Windschitl, Harold E., Sargent, Daniel J. , Sinicrope, Frank A. , Alberts, Steven R. , Sargent, Daniel J

Clinical Cancer Research | July 1, 2008 | Volume: 14 | Issue: 13 | Pages: 4128-4133

10.1158/1078-0432.ccr-07-5160 | PMID 18593990 Get It

Abstract Purpose: Proapoptotic BH3-only proteins Bad and Bid initiate apoptosis by binding to regulatory sites on prosurvival Bcl-2 proteins to directly neutralize their function. We determined if expression of these proteins in colon cancers may account for differences in patient survival. Experimental Design: Tumor-node-metastasis stages II and III primary colon carcinomas from patients treated in 5-fluorouracil-based adjuvant therapy trials were studied. Immunohistochemical analysis of Bad and Bid proteins was done in tumors (n = 379) and adjacent normal mucosa. Expression was correlated with clinicopathologic variables, disease-free survival rates (DFS), and overall survival (OS) rates. Results: High expression of the Bad protein [hazard ratio (HR), 0.64; 95% confidence interval (95% CI), 0.43-0.96; P = 0.031] in the cytoplasm of tumor cells was significantly associated with more favorable OS in a univariate analysis. The combined Bad and Bid variable was prognostic for DFS (P = 0.027) and OS (P = 0.006). Stage and histologic grade, but not DNA mismatch repair status, were also prognostic for OS. Multivariate Cox analysis showed that high expression of Bad (HR, 0.64; 95% CI, 0.43-0.97; P = 0.027) and Bid (HR, 0.68; 95% CI, 0.49-0.97; P = 0.034) were independent predictors of OS after adjustment for stage, grade, age, treatment, and study. The combined variable of Bad + Bid was independently associated with DFS (P = 0.020) and OS (P = 0.004). Conclusion: Proapoptotic Bad and Bid proteins are independent prognostic variables in colon cancer patients receiving adjuvant treatment. If validated, Bad and Bid expression may assist in risk stratification and selection of patients to receive adjuvant chemotherapy.
Prognostic Significance of Defective Mismatch Repair and BRAF V600E in Patients with Colon Cancer
French, Amy J. , Sargent, Daniel J. , Burgart, Lawrence J., Foster, Nathan R. , Kabat, Brian, Goldberg, Richard M. , Shepherd, Lois E. , Windschitl, Harold E., Thibodeau, Stephen N. , Sargent, Daniel J

Clinical Cancer Research | June 2, 2008 | Volume: 14 | Issue: 11 | Pages: 3408-3415

10.1158/1078-0432.ccr-07-1489 | PMID 18519771 Get It

Abstract Purpose: Colon tumors with defective DNA mismatch repair (dMMR) have a well-characterized phenotype and accounts for ∼15% to 20% of sporadic colon cancer as well as those colon cancer patients with Lynch syndrome. Although the presence of dMMR seems to be a favorable prognostic marker, data suggest that these patients do not respond as well to adjuvant chemotherapy. Experimental Design: In this study, we examined the prognostic significance of tumor MMR deficiency and the presence of a specific mutation in BRAF (V600E) in a group of patients (n = 533) who participated in a randomized prospective clinical trial through the North Central Cancer Treatment Group. Results: Tumors with dMMR were found to be associated with higher tumor grade (P = 0.001), proximal location (P < 0.0001), and improved overall and disease-free survival (P = 0.05 and 0.04, respectively). Among all cases examined, evaluation of the BRAF V600E mutation status revealed no statistically significant differences in either disease-free or overall survival. Patients were then grouped into four categories for further analysis: dMMR/BRAF(−), dMMR/BRAF(+), pMMR/BRAF(−), and pMMR/BRAF(+). The dMMR/BRAF(−) group had a significantly improved overall survival (5-year overall survival of 100% versus 73%, P = 0.002) compared with all others. The remaining three groups had very similar survival outcomes. An additional cohort of tumors previously classified as having dMMR were also tested for the BRAF V600E alteration. Results remained significant (P = 0.006) when the two groups were combined for analysis. Conclusions: Overall, these data suggest that the underlying molecular etiology of those tumors having dMMR may influence the disease outcome in these patients.